Filing Details

Accession Number:
0001127602-22-019253
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-07-12 17:55:04
Reporting Period:
2022-04-21
Accepted Time:
2022-07-12 17:55:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492422 Apellis Pharmaceuticals Inc. APLS Pharmaceutical Preparations (2834) 271537290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1773588 J. Adam Townsend C/O Apellis Pharmaceuticals, Inc.
100 Fifth Avenue, 3Rd Floor
Waltham MA 02451
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-04-21 1,875 $0.00 42,138 No 4 J Direct
Common Stock Acquisiton 2022-07-11 5,000 $15.09 47,907 No 4 M Direct
Common Stock Disposition 2022-07-11 5,000 $48.42 42,907 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 J Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-04-21 11,250 $0.00 11,250 $44.90
Common Stock Stock Option (Right to Buy) Disposition 2022-07-11 5,000 $0.00 5,000 $15.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2031-01-27 No 4 J Direct
370,000 2028-11-15 No 4 M Direct
Footnotes
  1. This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
  2. This is a scheduled exercise and sale form an established 10b5-1 plan.
  3. This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
  4. This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.